Global Markets Direct’s, 'Cardiovascular Risk Factors - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cardiovascular Risk Factors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiovascular Risk Factors. Cardiovascular Risk Factors - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Cardiovascular Risk Factors. - A review of the Cardiovascular Risk Factors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cardiovascular Risk Factors pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Cardiovascular Risk Factors. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cardiovascular Risk Factors pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Number of Products under Development for Cardiovascular Risk Factors, H1 2013 27 Products under Development for Cardiovascular Risk Factors - Comparative Analysis, H1 2013 28 Products under Development by Companies, H1 2013 29 Products under Investigation by Universities/Institutes, H1 2013 37 Late Stage Products, H1 2013 39 Mid Clinical Stage Products, H1 2013 40 Early Clinical Stage Products, H1 2013 41 Discovery and Pre-Clinical Stage Products, H1 2013 42 Assessment by Monotherapy Products, H1 2013 144 Assessment by Combination Products, H1 2013 145 Assessment by Route of Administration, H1 2013 146 Assessment by Stage and Route of Administration, H1 2013 147 Assessment by Molecule Type, H1 2013 149 Assessment by Stage and Molecule Type, H1 2013 150